Tosh joins the podcast to talk through Navigator Medicines' bispecific approach to Hidradenitis Suppurativa.

Giving us the full picture, from NAV-240's Korean-origins & the 2024 $100million Series A lead by RA Capital & Forbion, to the work that went into their half-life extended next-gen molecule NAV-242 & the speedy clinical development plan that could lead to a step change in HS patient outcomes.

We also discuss Tosh's learnings from a career in big pharma across the likes of GSK & AZ, why he had to 'scratch' his biotech 'itch' & the career learnings he's taking into his role at Navigator.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Max Brennan - Biotech HeadHunter. Innehållet i podden är skapat av Max Brennan - Biotech HeadHunter och inte av, eller tillsammans med, Poddtoppen.